MSLN and neoplasm: Further antigens were considered, including MSLN, since it is expressed in 69% of lung adenocarcinoma (1/5 patients) and not in normal lung tissues and reduced tumor burden in mouse models (Carpenito et al., 2009; Kachala et al., 2014).